On-treatment and projected sustained viral responses with boceprevir-based triple therapy in previous treatment-failure HCV patients with advanced fibrosis or cirrhosis. Interim a…
B Hunyady, M Abonyi, K Csefkó, A Haragh, G Horváth, V Jancsik, M Makara, E Makkai, Z Müller, Z Ozsvár, P Ribiczey, B Sipos, O Szabó, F Szalay, L Szentgyörgyi, E Újhelyi, M Varga, G Weisz · Zeitschrift für Gastroenterologie · 2013 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background and Aims: Efficacy and safety of boceprevir+peginterferon/ribavirin (B+PR) therapy in pervious treatment failure HCV genotype 1 pts with advanced liver fibrosis (F3) or cirrhosis (F4) have been analyzed, with special attention to previous null-responder cirrhotics. Methods: Real life data of the Hungarian Boceprevir Named Patient Program have been retrospectively collected. Treatment: 4-weeks PR lead-in, followed by 44 weeks B+PR therapy according to label (no response guided therapy), with w12 (HCV RNA> 100 IU/mL) and w24 (HCV RNA> 15 IU/mL) futility rules. Intent to treat (ITT) w24 (N = 148), per pr…
